Tretichnyy pokazatel' Glisona kak faktor prognoza retsidiva raka predstatel'noy zhelezy


Cite item

Full Text

Abstract

References

  1. Воробьев А.В. Рак предстательной железы: эволюция взглядов. Вопр. онкологии. 2009; 55 (2): 241-9.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2011; 22 (3).
  3. Han M, Partin AW, Chan DY et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004; 171: 23-6.
  4. Ahyai SA, Zacharias M, Isbarn H et al. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. BJU International 2010; 106 (4): 478-83.
  5. Graefen M, Walz J, Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006; 49: 38-48.
  6. Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152 (5 Pt. 2): 1850-7.
  7. Liu L, Coker AL, Du XL et al. Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. J Surgical Oncol 2008; 97: 583-91.
  8. Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997; 278 (1): 44-6.
  9. Kupelian PA, Katcher J, Levin HS et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043-52.
  10. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42.
  11. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.J Urol 1994; 152 (5): 1831-6.
  12. Frazier HA, Robertson JE, Humphrey PA et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993; 149 (3): 516-8.
  13. Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167 (2 Pt. 1): 528-34.
  14. Grossfeld GD, Chang JJ, Broering JM et al. Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy: data from the CAPSURE database. Urology 2000; 56 (3): 430-5.
  15. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-23.
  16. Amling CL, Blute ML, Bergstralh EJ et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164 (2): 101-5.
  17. Roehl KA, Han M, Ramos CG et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172 (3): 910-14.
  18. Porter CR, Gallina A, Kodama K et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2007; 52 (2): 446-52.
  19. Boorjian SA, Karnes RJ, Crispen PL et al. The impact of PSMs on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 2010; 183: 1003-9.
  20. Bianco FJ, Vickers AJ, Cronin AM et al. Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol 2010; 183: 977-82.
  21. Uhlman MA, Sun L, Stackhouse DA et al. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology 2010; 75: 460-6.
  22. Pfitzenmaier J, Pahernik S, Tremmel T et al. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int 2008; 102: 1413-8.
  23. Freedland SJ, Humphreys EB, Mangold LA et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25: 1765-71.
  24. Humphrey P. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathol 2004; 17: 292-306.
  25. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42.
  26. Lerner SE, Blute ML, Bergstralh EJ et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996; 156: 137-43.
  27. Epstein JI, Partin AW, Sauvageot J et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286-92.
  28. Green GA, Hanlon AL, Al-Saleem T et al. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 1998; 83: 971-6.
  29. Zagars GK, Ayala AG, Von Eschenbach AC et al. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1995; 31: 237-45.
  30. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42.
  31. Gilliland FD, Hoffman RM, Hamilton A et al. Predicting extra capsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J Urol 1999; 162 (4): 1341-5.
  32. Pan CC, Potter SR, Partin AW et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000; 24: 563-9.
  33. Epstein JI, Allsbrook WC, Amin MB et al. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-42.
  34. Egevad L, Granfors T, Karlberg L et al. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol 2002; 168: 509-13.
  35. Rasiah KK, Stricker PD, Haynes AM et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003; 98: 2560-5.
  36. Mosse CA, Magi-Galluzzi C, Tsuzuki T. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004; 28: 394-8.
  37. Hattab EM, Koch MO, Eble JN et al. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol 2006; 175: 1695-9.
  38. Harnden P, Shelley MD, Coles B et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007; 8: 411-9.
  39. Sim HG, Telesca D, Culp SH et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008; 179: 1775-9.
  40. Whittemore DE, Hick EJ, Carter MR et al. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008; 179: 516-22.
  41. Ruijter ET, Van De Kaa CA, Schalken JA et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996; 180: 295-9.
  42. Harnden P, Shelley MD, Coles B et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007; 8 (5): 411-9.
  43. Patel AA, Chen MH, Renshaw AA et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298 (13): 1533-8.
  44. Turker P, Bas E, Bozkurt S et al. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival. Urol Oncol 2011.
  45. Hashine K, Yuasa A, Shinomori K et al. Tertiary Gleason pattern 5 and oncological outcomes after radical prostatectomy. Jpn J Clin Oncol 2011; 41 (4): 571-6.
  46. Isbarn H, Ahyai SA, Chun FK et al. Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol 2009; 55 (2): 394-401.
  47. Oort IM, Schout BM, Kiemeney LA et al. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer? Eur Urology 2005; 48 (4): 572-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies